Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postmortem studies in schizophrenia

P Powchik1, M Davidson, V Haroutunian

  • 1Pfizer, Inc., New York, NY 10017, USA.

Schizophrenia Bulletin
|August 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blast-related disinhibition and risk seeking in mice and combat Veterans: Potential role for dysfunctional phasic dopamine release.

Neurobiology of disease·2017
Same author

Microprobe studies of aluminum accumulation in association with human central nervous system disease.

Environmental geochemistry and health·2013
Same author

Characterizing cognitive deficits and dementia in an aging urban population in India.

International journal of Alzheimer's disease·2012
Same author

Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

Current Alzheimer research·2011
Same author

Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons.

Neurology·2009
Same author

Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology.

Neurology·2008
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

Schizophrenia neuropathology lacks classical findings. Cognitive impairment in schizophrenia may link to specific neurochemical deficits, not typical dementias.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Neuropathology

Background:

  • Renewed interest in schizophrenia neuropathology driven by advanced techniques.
  • Understanding cognitive dysfunction in elderly schizophrenia patients is crucial.
  • Schizophrenia's underlying brain dysfunction requires further investigation.

Purpose of the Study:

  • Investigate neuropathology of schizophrenia, focusing on cognitive impairment.
  • Examine chemical markers (e.g., neurotransmitters, neuropeptides) in schizophrenia.
  • Correlate biological findings with diagnosis, cognitive status, and symptoms.

Main Methods:

  • Postmortem neuropathological analysis of 100 schizophrenia cases.
  • Assessment of chemical markers: choline acetyltransferase, catecholamines, indolamines, neuropeptides, synaptic proteins.

Related Experiment Videos

  • Correlation of neuropathological and chemical findings with antemortem cognitive and symptom data.

    • Main Results:

    • No classical, histologically identifiable neuropathology found in schizophrenia.
    • Schizophrenia cases did not show overall cholinergic or catecholamine/indolamine deficits.
    • Cognitive impairment correlated with lower choline acetyltransferase and deficits in cortical noradrenergic/serotonergic systems.
    • Neuropeptide deficits differed from Alzheimer's disease patterns.
    • Increased synaptic protein activity in the cingulate cortex correlated with schizophrenia symptoms.

    Conclusions:

    • Schizophrenia is not characterized by classical neuropathology or typical dementing illnesses.
    • Specific neurochemical alterations, like cortical amine deficits, may underlie cognitive impairment in schizophrenia.
    • Neuropeptide deficits and synaptic organization may relate to diagnosis and symptoms, respectively.